Clinical experience with a new solvent detergent-treated intravenous immunoglobulin free of hypotensive effects.
To see if modifications to the processing of intravenous immunoglobulin to include a virus inactivation stage alter immunoglobulin G (IgG) resulting in hypotension in patients. Clinical trials were done involving extensive patient monitoring during infusion: in vitro - testing for markers of hypotension, and in vivo - an animal model which closely simulates clinical use. No hypotensive response was seen in the animal model or clinical trial. The production process used does not damage IgG or create vaso-active kinins as the preparation was free of hypotensive effects.